135 related articles for article (PubMed ID: 35740571)
21. Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives.
Panthi VK; Dua K; Singh SK; Gupta G; Hansbro PM; Paudel KR
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111677
[TBL] [Abstract][Full Text] [Related]
22. Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma.
Pande R; Chughtai S; Ahuja M; Brown R; Bartlett DC; Dasari BV; Marudanayagam R; Mirza D; Roberts K; Isaac J; Sutcliffe RP; Chatzizacharias NA
World J Gastrointest Surg; 2022 May; 14(5):429-441. PubMed ID: 35734625
[TBL] [Abstract][Full Text] [Related]
23. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan.
Lai HL; Chen YY; Lu CH; Hung CY; Kuo YC; Chen JS; Hsu HC; Chen PT; Chang PH; Hung YS; Chou WC
Cancer Med; 2019 May; 8(5):2085-2094. PubMed ID: 31001907
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
[TBL] [Abstract][Full Text] [Related]
25. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
26. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma.
Qian L; Yu S; Yin C; Zhu B; Chen Z; Meng Z; Wang P
Pancreatology; 2019 Mar; 19(2):340-345. PubMed ID: 30685120
[TBL] [Abstract][Full Text] [Related]
27. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
28. Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
Zou YP; Li WM; Zheng F; Li FC; Huang H; Du JD; Liu HR
World J Gastroenterol; 2010 Oct; 16(40):5104-10. PubMed ID: 20976848
[TBL] [Abstract][Full Text] [Related]
29. Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.
Ugurel S; Loquai C; Terheyden P; Schadendorf D; Richtig E; Utikal J; Gutzmer R; Rass K; Sunderkötter C; Stein A; Fluck M; Kaatz M; Trefzer U; Kähler K; Stadler R; Berking C; Höller C; Kerschke L; Edler L; Kopp-Schneider A; Becker JC
Oncotarget; 2017 Sep; 8(44):76029-76043. PubMed ID: 29100289
[TBL] [Abstract][Full Text] [Related]
30. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
31. Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma.
Gao Y; Chen S; Vafaei S; Zhong X
Front Oncol; 2020; 10():557638. PubMed ID: 33102222
[TBL] [Abstract][Full Text] [Related]
32. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
33. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
34. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
35. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
Cazzaniga ME; Biganzoli L; Cortesi L; De Placido S; Donadio M; Fabi A; Ferro A; Generali D; Lorusso V; Milani A; Montagna E; Munzone E; Orlando L; Pizzuti L; Simoncini E; Zamagni C; Pappagallo GL;
Onco Targets Ther; 2019; 12():2989-2997. PubMed ID: 31114242
[TBL] [Abstract][Full Text] [Related]
36. Endoscopic ultrasound-guided injectable therapy for pancreatic cancer: A systematic review.
Kaur J; Jaruvongvanich V; Chandrasekhara V
World J Gastroenterol; 2022 Jun; 28(21):2383-2395. PubMed ID: 35800184
[TBL] [Abstract][Full Text] [Related]
37. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
38. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
Xu B; Sun T; Wang S; Lin Y
Expert Rev Anticancer Ther; 2021 Jan; 21(1):71-79. PubMed ID: 33054438
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
40. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
